UHS · Universal Health Services Inc
$170.02
-1.19 (-0.70%)
At close · Aug 14
Market Cap
$10.02B
Shares
58.94M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$170.02
Open$171.19
Day$169.45–172.33
52W close$141.17–244.18
Avg vol 30d904K
Short int3.0M · 5.1% float · 2.6d
Short vol66%
Last earningsJul 28, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+10%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
28%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−27%
trailing
YTD return
−22%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $155 › 200d $190 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +67 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.09% of float · ▼ -11.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
584 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
EPS growth
+37%
Y/Y
Free cash flow
$849.2M
Valuation
P/E 6.9
below peers
Buyback
$977.6M
remaining
Balance sheet
$4.6B
net debt
Quant / Vol
risk profile
Volatility
32%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Same-facility acute care adjusted admissions growth
· full year
1.5% – 2.5%
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2025
2025 EPS guidance
· 2025 full year
$20.50
Net benefit from previously approved state Medicaid supplemental
· 2025 full year
$1.2B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+10%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
28%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $155 › 200d $190 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +67 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.09% of float · ▼ -11.8% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
584 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $141
Now $170 · 28%
Range high $244
vs 200-day avg -10%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted admissions (acute care, same facility basis) | 1.4% | first six months of 2026 | — |
| Adjusted admissions (behavioral health care, same facility basis) | 0.5% | second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA net of NCI non-GAAP | 1.33B | first six months of 2026 | — |
|
|
|||
| Adjusted patient days (acute care, same facility basis) | 1.9% | first six months of 2026 | — |
|
|
|||
| Adjusted patient days (behavioral health care, same facility basis) | 1.4% | second quarter of 2026 | — |
|
|
|||
| EBITDA net of NCI | 1.33B | first six months of 2026 | — |
|
|
|||
| Net revenue per adjusted admission (acute care, same facility basis) | 4.6% | first six months of 2026 | — |
| Net revenue per adjusted admission (behavioral health care, same facility basis) | 7.1% | second quarter of 2026 | — |
|
|
|||
| Net revenue per adjusted patient day (acute care, same facility basis) | 4.2% | first six months of 2026 | — |
|
|
|||
| Net revenue per adjusted patient day (behavioral health care, same facility basis) | 6.1% | second quarter of 2026 | — |
|
|
|||
| Net revenues (acute care services, same facility basis) | 8.2% | first six months of 2026 | — |
|
|
|||
| Net revenues (behavioral health care services, same facility basis) | 7.3% | first quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UHS
this stock
Universal Health Services Inc
|
$10.02B | -22.0% | +9.7% | 6.9 | 5.1% |
|
HCA
HCA Healthcare, Inc.
|
$89.77B | -13.3% | +7.1% | 13.9 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.87B | -4.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.57B | +34.8% | +0.9% | 10.3 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.65B | -0.2% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UHS | -2.0% | +12.5% | -26.9% | +0.9% | -22.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.4% | +8.0% | -40.7% | -3.0% | -35.9% |
Capital returns
Latest dividend
$0.20
/ share · ex Jun 8, 2026
Declared · upcoming
$0.20
/ share · ex Sep 1, 2026
Paid (TTM)
$0.80
/ share · 4 payouts
Dividend yield (TTM, derived)
0.47%
Buyback programs
· 3 active
· as of Jun 30, 2026
Authorized (total)
$5.00B
Spent (derived)
$4.02B
Remaining
$977.60M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
352915
CUSIP
913903100
13F (30d)
554 filings
536 filers
Visit website
Investor relations